News & Updates
Filter by Specialty:
Self-adjusted nitrous oxide eases pain during transrectal prostate biopsy
Patient use of self-adjusted nitrous oxide (N2O) at levels of 20 percent to 45 percent during transrectal prostate biopsy is safe and well tolerated, according to a study. Delivery of low-dose N2O is associated with reduced pain, but its effect on anxiety does not seem significant.
Self-adjusted nitrous oxide eases pain during transrectal prostate biopsy
30 Jan 2024Does drinking alkaline water help people with uric acid, cystine urolithiasis?
Consumption of commercially available alkaline water does not provide significant benefits, partially because of its negligible alkali content, over tap water for patients with uric acid and cystine urolithiasis, reports a study.
Does drinking alkaline water help people with uric acid, cystine urolithiasis?
30 Jan 2024ED, vaginismus shut out sex in married couples
Unconsummated marriage (UCM) among heterosexual couples is typically caused by erectile dysfunction (ED) and vaginismus, according to a study, noting however that a strong psychological component plays a major role in many of these cases.
ED, vaginismus shut out sex in married couples
28 Jan 2024Survivors cope with life after testicular cancer
Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.
Survivors cope with life after testicular cancer
13 Jan 2024Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023MAGNITUDE updates in Asian cohort boost NIRA-AAP benefit in BRCA+ mCRPC
In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).